Study · Case report or series · n = 1 · 2025

1 result

Non arteritic ischemic optic neuropathy in a patient taking semaglutide: Is there a relation? A case report and a review of the literature.

Maceroni M, Sasso P, Giarletti M, Bruno V, Minnella AM

European journal of ophthalmology4 Apr 2025Cited by 3 (Europe PMC)

PMID40183385DOI10.1177/11206721251331655PepBankPUB-40183385

Publisher page PubMedAsk about this study

Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

01HumanCase report or seriesSafety outcome
A case of non-arteritic anterior ischemic optic neuropathy occurred in a diabetic patient taking semaglutide; the authors review whether the drug is related.
In plain wordsOne diabetic patient taking semaglutide developed a type of optic nerve damage; the link to the drug is not established.
Peptide
Semaglutide
Outcome
Not applicableNon-arteritic anterior ischemic optic neuropathy
Study
n = 1
Outcome group
Adverse events · Eye
Studied dose
Dose not stated
Source sentences
Summary
report a case of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) occurring in a diabetic patient taking Semaglutide
Report a problemFND-4018338501

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.